Improved Orthopedic Implant Surface Coatings

腔内金属植入物是医学和牙科常用的同种异体材料。这个 整形外科和牙科市场继续增长，植入物的适应症正在扩大。人们认为有必要通过控制愈合和重塑过程中的界面反应性来改善种植体的成功愈合(骨整合)和长期结果。骨生物学知识的增长和生物技术的发展使得目前考虑通过使用天然或合成的生物活性物质(生长因子、细胞外基质蛋白、小分子)来将一种或多种界面生物活性指定给骨内金属种植体。相关界面作用的潜在例子包括BMPs指定的成骨诱导、OPG指定的抑制吸收、抑制 炎症性TNFR拮抗剂，或通过抗微生物或抗污染分子预防感染。每一种界面作用都与当今使用的一种或多种骨内金属植入物应用相关。将一种或多种生物活性直接规范到骨内金属种植体表面所面临的主要障碍是在不损害种植体的基本机械性能或特定生物活性物质的功能的情况下将指定剂附着到金属表面。 在这项建议中，我们提出了一种新的方法来确定钛种植体表面的生物活性。AffinEnergy已经开发出一种通用的方法来创建目标表面特定的生物聚合物，这种聚合物不可逆地将特定的生物活性物质结合到骨内植入表面。这些特定的和接枝的生物聚合物被称为“界面生物材料”(IFBM)。双功能IFBM具有以下独特优点：a)提供必要的表面结合专一性，b)包括用于广泛应用的强健化学，以及c)提供指定广泛相关或独立生物的能力 在单一的金属表面上的活动。这一阶段SBIR提案的目标是验证IFBM方法，以确定钛骨内种植体的生物活性。本研究的结果将为IFBM修饰的骨内种植体直接转化为临床应用奠定基础。

Endosseous metallic implants are common alloplastic devices used in medicine and dentistry. The orthopedic and dental marketplace continues to grow and indications for implants are expanding. There is a perceived need to improve both the successful healing (osseointegration) and the long term outcome of implants by control of interfacial reactivity during healing and remodeling. The growth of knowledge of bone biology and the expansion of biotechnology permits the present consideration of specifying one or more interfacial biologic activities to an endosseous metallic implant by use of a natural or synthetic bioactive agent (growth factor, extracellular matrix protein, small molecule). Potential examples of relevant interfacial actions include osteoinduction specified by BMPs, inhibition of resorption specified by OPG, inhibition of inflammation TNFR antagonists, or prevention of infection by anti-microbial or anti-fouling molecules. Each interfacial action is of related significance to one or more endosseous metallic implant application used today. The main obstacle facing the direct specification of a biological activity or activities to an endosseous metallic implant surface is the attachment of the specifying agent to the metallic surface without compromising the underlying mechanical properties of the implant or the function of the specifying bioactive agent. In this proposal we present a novel approach for specifying the biologic activity of titanium implant surfaces. Affinergy has developed a generalized approach to creating target surface-specific biopolymers that irreversibly bind specifying bioactive agents to the endosseous implant surface. These specifying and grafting biopolymers are termed a "interfacial biomaterials" (IFBM). The bi-functional IFBM has the unique advantages of a) providing requisite surface binding specificity, b) comprising robust chemistry for broad-based applications and c) offering capacity to specify a wide range of associated or independent biological activities onto a single metallic surface. The goal of this phase I SBIR proposal is to validate the IFBM approach to specifying a biological activity to titanium endosseous implants. The results of this research will establish the foundation for direct translation of IFBM-modified endosseous implants to clinical applications.